Risperidone sustained release microsphere composition

US9446135B2 · kind B2 · utility

Assignee

• SHANDONG LUYE PHARMACEUTICAL CO., LTD. · CN

Inventors

• Kaoxiang Sun · Yantai, CN
• Rongcai Liang · Yantai, CN
• Qilin Wang · Brisbane, AU
• Wenyan Wang · Wilmette, US
• Wanhui Liu · Yantai, CN
• Youxin Li · Langenfeld, DE

Key dates

• Filing date: Apr 10, 2012
• Grant date: Sep 20, 2016
• Expiry date: Apr 10, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.